Cipla Ltd (CIPL.NS)
425.60INR
17 May 2013
Rs3.50 (+0.83%)
Rs408.05
Rs422.00
Rs428.00
Rs415.70
2,126,588
1,300,517
Rs435.00
Rs300.00
CIPL.NS
About
Overall
| Beta: | 0.39 |
| Market Cap (Mil.): | Rs341,723.31 |
| Shares Outstanding (Mil.): | 802.92 |
| Dividend: | 2.00 |
| Yield (%): | 0.47 |
Financials
| CIPL.NS | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 34.53 | 35.66 | 35.83 |
| EPS (TTM): | 12.32 | -- | -- |
| ROI: | 14.28 | 19.36 | 18.72 |
| ROE: | 15.74 | 20.07 | 19.54 |
Cipla Medpro shareholders back buyout by India's Cipla
JOHANNESBURG - Shareholders of South Africa's Cipla Medpro overwhelmingly approved a $488 million takeover offer from India's Cipla Ltd on Wednesday, giving the Indian drugmaker a big presence in Africa's biggest economy.
Cipla Medpro shareholders approve buyout by India's Cipla
JOHANNESBURG, May 15 - Cipla Medpro South Africa said on Wednesday its shareholders had approved a $500 million buyout offer from India's Cipla Ltd.
India's Cipla launches etanercept biosimilar
MUMBAI, April 17 - Indian drugmaker Cipla Ltd said on Wednesday it has launched etanercept biosimilar in India under the brand name Etacept.
MARKET EYE-Natco, Cipla up; India's top court dismisses Novartis petition
* Shares in Natco Pharma Ltd and Cipla Ltd gain after India's highest court dismissed Swiss drugmaker Novartis AG's petition seeking patent for its cancer drug Glivec. * In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law. * Analysts say that will be a big win for generic drugmakers given huge difference in prices of monopoly drugs, and as
India's Cipla should pay more for Medpro, says top shareholder
JOHANNESBURG, March 12 - A top shareholder in Cipla Medpro said on Tuesday it would ask India's Cipla Ltd to raise its $500 million offer for South Africa's third-largest generic drugs firm.
UPDATE 2-India's Cipla bids $500 mln for S.Africa affiliate
* Cipla Medpro shares up 1 pct, slightly below offer price (Recasts, adds more details on price)
India's Cipla plans $512 million takeover of South Africa's Cipla Medpro
MUMBAI - Indian drugmaker Cipla Ltd on Thursday sweetened its offer by 17 percent to take over South Africa's third-largest drugmaker, Cipla Medpro South Africa Ltd, ending the uncertainty of an earlier offer that had been put on hold by the Indian company.
India's Cipla offers to buy South Africa's Cipla Medpro for $512 mln
MUMBAI, Feb 28 - Indian drugmaker Cipla said it has offered to buy all shares in South Africa's third largest drugmaker Cipla Medpro for a total consideration of about $512 million.
India's Cipla puts $215 million South Africa bid on hold
JOHANNESBURG/MUMBAI - India's Cipla Ltd has put on hold a $215 million bid for control of South Africa's Cipla Medpro , signaling it may be unwilling to sweeten its offer for the drug firm.
India's Cipla Q3 net up 25.5 pct
MUMBAI, Feb 6 - Cipla Ltd, India's fifth largest drugmaker by sales, reported a 25.5 percent rise in quarterly profit on robust sales but slightly missed street estimates as taxes surged.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: News Bites Pty Limited
|
$5.00
|
|
Provider: News Bites Pty Limited
|
$5.00
|
|
Provider: News Bites Pty Limited
|
$5.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
